Hybridoma-based Anti-idiotypic mAb Discovery against a Bispecific Therapeutics for PK/ADA Assays Development

Case study showcasing a campaign for the discovery of panels of anti-idiotypic mAb’s for a bispecific molecule to be used for PK/ADA Assay Development.

Covered in this Case Study

Anti-idiotypic, bispecific discovery case study

Rapid immunization of 2 cohorts of mice. Screening by Elisa and Octet

Delivered: oHC/LC sequences and purified and validated mAb one week ahead of schedule

Share your details to Get the Case Study

Genes

Oligo Pools

NGS Target Enrichment Solutions

Variant Libraries

Synthetic Controls

Antibody Discovery

Hybridoma-based Anti-idiotypic mAb Discovery against a Bispecific Therapeutics for PK/ADA Assays Development

Related Resources

Twist cfDNA Pan-Cancer Reference standard VAF 0% (WT), 3ug (SDS-001098)

ANTI-IDIOTYPIC MAB DISCOVERY PART I: SCREENING STRATEGY FOR ANTI-IDIOTYPIC MAB (ANTI-ID) AS CRITICAL PK/ADA AS

Synthetic DNA: The Fabric of Modern Cancer Research